4548-56-5

Basic information

• Product Name: 4-CHLORO-2-NITRO-1-(PHENYLTHIO)BENZENE
• Synonyms: LABOTEST-BB LT01147670;4-CHLORO-2-NITRODIPHENYL SULFIDE;4-CHLORO-2-NITRO-1-(PHENYLTHIO)BENZENE
• CAS NO: 4548-56-5
• Molecular Formula: C₁₂H₈ClNO₂S
• Molecular Weight: 265.72
• Mol File: 4548-56-5.mol
• Article Data: 14

Chemical Properties

• Melting Point: 82 °C
• Boiling Point: 373°Cat760mmHg
• Flash Point: 179.4°C
• Appearance: /
• Density: 1.41g/cm³
• Vapor Pressure: 1.99E-05mmHg at 25°C
• Refractive Index: 1.674
• CAS DataBase Reference: 4-CHLORO-2-NITRO-1-(PHENYLTHIO)BENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2-NITRO-1-(PHENYLTHIO)BENZENE(4548-56-5)
• EPA Substance Registry System: 4-CHLORO-2-NITRO-1-(PHENYLTHIO)BENZENE(4548-56-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 4548-56-5(Hazardous Substances Data)

Usage

General Description

4-CHLORO-2-NITRO-1-(PHENYLTHIO)BENZENE is a chemical compound with the molecular formula C12H8ClNO3S. It is a nitrophenylthio derivative that contains a chlorine atom and a nitro group. 4-CHLORO-2-NITRO-1-(PHENYLTHIO)BENZENE is used in the synthesis of various pharmaceuticals and agrochemicals. It is also a valuable intermediate in organic synthesis, with applications in the production of dyes, pigments, and other fine chemicals. 4-CHLORO-2-NITRO-1-(PHENYLTHIO)BENZENE is a yellow crystalline solid with a melting point of 116-118°C and should be handled with care due to its potential toxic and irritant properties.

InChI:InChI=1/C12H8ClNO2S/c13-9-6-7-12(11(8-9)14(15)16)17-10-4-2-1-3-5-10/h1-8H

Upstream product

• 108-98-5 thiophenol 
• 89-61-2 2,5-dichloronitrobenzene 
• 787633-79-8 (R,S)-1-(4-chloro-2-nitrophenyl)ethanol 
• 882-33-7 diphenyldisulfane 
• 6280-88-2 4-chloro-2-nitro-benzoic acid 
• 930-69-8 sodium thiophenolate 
• 36776-27-9 4-chloro-2-nitro-thiophenol 
• 108-90-7 chlorobenzene 
• 610-40-2 3,4-dinitro-chlorobenzene 
• 64-17-5 ethanol 
• 345-18-6 2-fluoro-5-chloronitrobenzene 

Downstream Products

• 101096-34-8 N-(3-chloropropyl)-5-chloro-2-phenylthiophenylamine 
• 1451261-61-2 N-[5-chloro-2-(phenylsulfinyl)phenyl]-1-benzofuran-2-sulfonamide 
• 1451261-60-1 N-[5-chloro-2-(phenylsulfonyl)phenyl]-1-benzofuran-2-sulfonamide 
• 1451261-59-8 N-[5-chloro-2-(phenylsulfanyl)phenyl]-1-benzofuran-2-sulfonamide 
• 86030-10-6 5,5'-dichloro-2,2'-bis(thiophenoxy)azoxybenzene 
• 31520-27-1 5,5'-dichloro-2,2'-bis(thiophenoxy)azobenzene 
• 195073-76-8 3-Bromo-N-{5-chloro-2-[4-(2-methyl-[1,3]dioxolan-2-yl)-phenylsulfanyl]-phenyl}-propionamide 
• 195073-80-4 N-(3-bromopropyl)-5-chloro-2-(4-acetoxythiophenyl)phenylamine 
• 195073-75-7 N-[2-(4-Acetyl-phenylsulfanyl)-5-chloro-phenyl]-3-bromo-propionamide 
• 195073-72-4 2-Bromo-N-(5-chloro-2-phenylsulfanyl-phenyl)-acetamide 

Relevant articles and documents

BTB-1 A small molecule inhibitor of the mitotic motor protein kif18A

Turning the motor off: A malachite green based assay leads to the identification of BTB-1 (see picture), the first small-molecule inhibitor of the mitotic motor protein Kif18A. BTB-1 reversibly inhibits the ATPase activity of the recombinant motor domain

Quinazolinone and isoquinolinone derivative

The present invention relates to quinazolinone and isoquinolinone derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

Modulation of cAMP-specific PDE without emetogenic activity: New sulfide-like PDE7 inhibitors

A forward chemical genetic approach was followed to discover new targets and lead compounds for Parkinson's disease (PD) treatment. By analysis of the cell protection produced by some small molecules, a diphenyl sulfide compound was revealed to be a new phosphodiesterase 7 (PDE7) inhibitor and identified as a new hit. This result allows us to confirm the utility of PDE7 inhibitors as a potential pharmacological treatment of PD. On the basis of these data, a diverse family of diphenyl sulfides has been developed and pharmacologically evaluated in the present work. Moreover, to gain insight into the safety of PDE7 inhibitors for human chronic treatment, we evaluated the new compounds in a surrogate emesis model, showing nonemetic effects.